We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

IUdR/BUdR Cell Cycle Labelling

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00042250
Recruitment Status : Completed
First Posted : July 26, 2002
Last Update Posted : January 24, 2012
Sponsor:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
To determine cell cycle parameters and changes after treatment, the labelling agent is given and a bone marrow aspiration is accomplished before treatment and after treatment for comparison. Participants must be undergoing concurrent therapy for hematologic malignancy.

Condition or disease Intervention/treatment
Hematologic Malignancies Drug: Chemotherapy for hematologic malignancy

Detailed Description:
Cell cycle parameters include LI, Ts, Tc, T dpot, changes in these parameters, and differences between normal and leukemic cells in patients with hematologic malignancy prior to and following treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Cell Cycle Kinetics in Vivo in Patients With Hematologic Malignancies Studied by Iododeoxyuridine and Bromodeoxyuridine Labelling
Study Start Date : May 1992
Primary Completion Date : October 2002
Study Completion Date : October 2002




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Histologic proof of one of:

  • AML, ALL, or AUL
  • MDS or CMML
  • CML
  • OR undergoing bone marrow transplantation.

Participants should be:

  • off therapy for at least two weeks
  • At least 18 years old or older
  • Using adequate contraception if of child-bearing capability.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00042250


Locations
United States, Texas
M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Investigators
Study Chair: Michael Andreeff, MD, PhD M.D. Anderson Cancer Center

Additional Information:
Responsible Party: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00042250     History of Changes
Other Study ID Numbers: DM91-102
First Posted: July 26, 2002    Key Record Dates
Last Update Posted: January 24, 2012
Last Verified: January 2012

Keywords provided by M.D. Anderson Cancer Center:
Cell Cycle Interphase
G0
G1
G2
S Phase

Additional relevant MeSH terms:
Neoplasms